Search

Search Constraints

You searched for: Author/Creator Yilmaz, Musa

Search Results

1. Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. Issue 7 (29th April 2019)

2. Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis. Issue 15 (15th April 2019)

3. Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic‐phase chronic myeloid leukemia. Issue 13 (3rd May 2018)

4. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Issue 18 (31st May 2019)

5. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3‐internal tandem duplication mutation–positive acute myeloid leukemia. Issue 21 (16th July 2019)

6. Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia. Issue 1 (25th September 2019)

7. Phase 2 study of hyper‐CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Issue 7 (24th April 2020)

8. Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax. Issue 20 (13th July 2021)

9. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Issue 14 (6th December 2021)